Poland· PL-100159832
Intratect
A humane immunglobuline, unspezifisch, intravaskulär product containing immunoglobulinum humanum normale ad usum intravenosum, registered in Poland by Biotest Pharma GmbH. The same ATC class is registered in 11 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Humane immunglobuline, unspezifisch, intravaskulär is registered in 11 of 19 countries.
Countries holding a registration under ATC J06BA02 (humane immunglobuline, unspezifisch, intravaskulär), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Humane immunglobuline, unspezifisch, intravaskulär · ATC J06BA02
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
URPL (Poland)- Active substance
- Immunoglobulinum humanum normale ad usum intravenosum
- Manufacturer
- Biotest Pharma GmbH
- Country
- Poland (PL)
- ATC code
- J06BA02
- ATC class
- Humane Immunglobuline, unspezifisch, intravaskulär
- Defined daily dose
- 1.6 g, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 8
- gtin05909990571741
- gtin05909990571758
- gtin05909990571765
- gtin05909990571772
- gtin04036124001049
- gtin04036124000950
- gtin04036124001148
- gtin04036124001254
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
48 interactions on record for humane immunglobuline, unspezifisch, intravaskulär.
Graded by severity as the source publishes them — 44 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Humane immunglobuline, unspezifisch, intravaskulär · interactions on record
48 records
- 44 severe
- 4 minor
Most severe, free to view
- NeomycinA07AA01severe
- StreptomycinA07AA04severe
- Polymyxin BA07AA05severe
- Amphotericin BA07AA07severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Humane immunglobuline, unspezifisch, intravaskulär in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumCutaquig 165 mg/mlOctapharma Benelux
- United StatesAlygloGC Biopharma Corp.
- SpainBERIGLOBINA PCsl Behring S.A.
- FinlandCutaquigOctapharma AB
- SwedenBeriglobin 160 mg/ml Injektionsvätska, lösning i förfylld sprutaCSL Behring GmbH
- CzechiaGAMMANORMOctapharma (IP) SPRL, Brusel
- JapanｐＨ４処理酸性人免疫グロブリン（皮下注射）武田薬品工業
- GermanyBeriglobinCsl Behring Gmbh
Authorised across Europe · EMA
The same active substance is authorised in 30 EEA countries. Names it is sold under:
- Austria · Cutaquig, Cuvitru
- Belgium · Cutaquig, Cuvitru
- Bulgaria · Имуновенин, Интратект
- Cyprus · Gamunex, Intratect
- Czechia · Cutaquig, Cuvitru
- Germany · Beriglobin, Cutaquig
- Denmark · Cutaquig, Cuvitru
- Estonia · Cutaquig, Gammanorm
- Spain · Cutaquig, Cuvitru
- Finland · Cutaquig, Cuvitru
- France · Clairyg, Cutaquig
- United Kingdom (Northern Ireland) · Cutaquig, Cuvitru
- Greece · Gaminex, Ig Vena
- Croatia · Cutaquig, Ig Vena
- Hungary · Cutaquig, Gammanorm
- Ireland · Cutaquig, Cuvitru
- Iceland · Cutaquig, Deqsiga
- Italy · Cutaquig, Cuvitru
- Liechtenstein · Deqsiga, Flebogamma Dif
- Lithuania · Cutaquig, Gammanorm
- Luxembourg · Cutaquig, Gammagard S/D (Solvent/Detergent)
- Latvia · Cutaquig, Gammanorm
- Malta · Cutaquig, Gammanorm
- Netherlands · Cutaquig, Cuvitru
- Norway · Cutaquig, Cuvitru
- Portugal · Cutaquig, Gammanorm
- Romania · Cutaquig, Gammanorm
- Sweden · Cutaquig, Cuvitru
- Slovenia · Cutaquig, Gammanorm
- Slovakia · Cutaquig, Cuvitru
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c0764864-8595-49aa-8eab-21f69b54834d GET /v1/drugs/c0764864-8595-49aa-8eab-21f69b54834d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do infuzji",
"source": "urpl",
"strength": "50 g/l (50 mg/ml)",
"packaging": "05909990571741 ¦ Rp ¦ Skasowane ¦ 32485\n1 fiol. 20 ml\n05909990571758 ¦ Rp ¦ Skasowane ¦ 32486\n1 fiol. 50 ml\n05909990571765 ¦ Rp ¦ Skasowane ¦ 32487\n1 fiol. 100 ml\n05909990571772 ¦ Rp ¦ Skasowane ¦ 32488\n1 fiol. 200 ml\n04036124001049 ¦ Rp ¦ 133797\n1 fiol. 50 ml\n04036124000950 ¦ Rp ¦ 133798\n1 fiol. 20 ml\n04036124001148 ¦ Rp ¦ 133799\n1 fiol. 100 ml\n04036124001254 ¦ Rp ¦ 133800\n1 fiol. 200 ml",
"substance": "Immunoglobulinum humanum normale",
"common_name": "Immunoglobulinum humanum normale ad usum intravenosum",
"pl_product_id": "100159832",
"pozwolenie_nr": "12115",
"auth_procedure": "MRP",
"authorisation_validity": "Bezterminowe"
}See everything about humane immunglobuline, unspezifisch, intravaskulär.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.